Santen Pharmaceutical Co Statistics
Santen Pharmaceutical Co (SZD0) Stock Statistics & Valuation Metrics
Total Valuation
Santen Pharmaceutical Co has a market cap or net worth of EUR 3.66B. The enterprise value is EUR 3.13B.
- Market Cap
- EUR 3.66B
- Enterprise Value
- EUR 3.13B
Share Statistics
Santen Pharmaceutical Co has 322,314,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 322,314,150
- Owned by Insiders
- ―
- Owned by Institutions
- 0.01%
Financial Efficiency
Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 11.16%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 11.16%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 77.93M
- Profits Per Employee
- 9.99M
- Employee Count
- 3,968
- Asset Turnover
- 0.73
- Inventory Turnover
- 2.14
Valuation Ratios
The current PE Ratio of Santen Pharmaceutical Co is 16.64. Santen Pharmaceutical Co’s PEG ratio is 0.56.
- PE Ratio
- 16.64
- PS Ratio
- 2.17
- PB Ratio
- 2.12
- Price to FCF
- 15.58
- Price to Operating Cash Flow
- 12.98
- PEG Ratio
- 0.56
Income Statement
In the last 12 months, Santen Pharmaceutical Co had revenue of 309.21B and earned 39.62B in profits. Earnings per share was 121.43.
- Revenue
- 309.21B
- Gross Profit
- 170.68B
- Operating Income
- 47.94B
- Pretax Income
- 50.30B
- Net Income
- 39.62B
- EBITDA
- 67.41B
- Earnings Per Share (EPS)
- 121.43
Cash Flow
In the last 12 months, operating cash flow was 50.62B and capital expenditures -12.29B, giving a free cash flow of 38.33B billion.
- Operating Cash Flow
- 50.62B
- Free Cash Flow
- 38.33B
- Free Cash Flow per Share
- 128.42
Dividends & Yields
Santen Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of 1.81%
- Dividend Per Share
- ―
- Dividend Yield
- 1.81%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.45%
- Earnings Yield
- 6.06%
Stock Price Statistics
- Beta
- 0.12
- 52-Week Price Change
- 34.12%
- 50-Day Moving Average
- 9.83
- 200-Day Moving Average
- 9.97
- Relative Strength Index (RSI)
- 96.54
- Average Volume (3m)
- ―
Important Dates
Santen Pharmaceutical Co upcoming earnings date is Feb 09, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 09, 2027
- Ex-Dividend Date
- ―
Financial Position
Santen Pharmaceutical Co as a current ratio of 2.60, with Debt / Equity ratio of 11.70%
- Current Ratio
- 2.60
- Quick Ratio
- 1.87
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- -0.69
- Interest Coverage Ratio
- 22.68
Taxes
In the past 12 months, Santen Pharmaceutical Co has paid 10.48B in taxes.
- Income Tax
- 10.48B
- Effective Tax Rate
- 0.21
Enterprise Valuation
Santen Pharmaceutical Co EV to EBITDA ratio is 8.67, with an EV/FCF ratio of 14.32.
- EV to Sales
- 1.99
- EV to EBITDA
- 8.67
- EV to Free Cash Flow
- 14.32
- EV to Operating Cash Flow
- 11.91
Balance Sheet
Santen Pharmaceutical Co has EUR 82.75B in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 82.75B billion.
- Cash & Marketable Securities
- EUR 82.75B
- Total Debt
- EUR 0.00
- Net Cash
- EUR 82.75B
- Net Cash Per Share
- EUR 256.74
- Tangible Book Value Per Share
- EUR 727.45
Margins
Gross margin is 56.15%, with operating margin of 15.74%, and net profit margin of 13.09%.
- Gross Margin
- 56.15%
- Operating Margin
- 15.74%
- Pretax Margin
- 16.72%
- Net Profit Margin
- 13.09%
- EBITDA Margin
- 22.95%
- EBIT Margin
- 16.85%
Analyst Forecast
The average price target for Santen Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -8.31%
- EPS Growth Forecast
- 17.13%
Scores
- Smart Score
- 4
- AI Score
- ―
